Unlock instant, AI-driven research and patent intelligence for your innovation.

Use of biomarkers for preparing diagnostic reagents for cystitis glandularis

A diagnostic reagent, cystitis technology, applied in the field of diagnostic reagents, can solve the problem of lack of characteristic clinical manifestations of cystitis glandularis

Active Publication Date: 2019-11-08
北京华瑞康源生物科技发展有限公司
View PDF1 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

Due to the lack of characteristic clinical manifestations of cystitis glandularis and the defects and deficiencies of the existing inspection methods, it is necessary to develop relevant diagnostic reagents to diagnose and classify cystitis glandularis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of biomarkers for preparing diagnostic reagents for cystitis glandularis
  • Use of biomarkers for preparing diagnostic reagents for cystitis glandularis
  • Use of biomarkers for preparing diagnostic reagents for cystitis glandularis

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0033] Example 1 Diagnostic reagents based on blood circulation miRNA molecules

[0034] Part 1: Screening Phase

[0035] 1. Experimental materials and experimental methods

[0036] 1. Plasma samples: 23 subjects, aged 45-55 years, with an average of 51.3 years; 12 males and 11 females. Grouping confirmed by cystoscopy: chronic inflammation group (6 cases of chronic inflammation type, 3M / 3F), follicular edema group (5 cases of follicular edema type, 3M / 2F), papilloma group (5 cases of papilloma type, 2M / 3F), intestinal adenomatous group (7 cases of intestinal adenomatous type, 4M / 3F). All cases were newly diagnosed and had no history of drug treatment. Another 5 cases with normal bladder served as the control group. There was no significant difference in the age of the subjects in each group. All patients and those with normal bladder had normal heart, lung, liver, kidney and hematopoietic functions. Normal bladder refers to healthy volunteers with no abnormal prolifera...

Embodiment 2

[0060] Example 2 Diagnostic reagents based on plasma small molecule metabolites

[0061] Part 1: Screening Phase

[0062] 1. Experimental materials and experimental methods

[0063] 1. Plasma samples: 23 subjects, aged 45-55 years, with an average of 51.3 years; 12 males and 11 females. Grouping confirmed by cystoscopy: chronic inflammation group (6 cases of chronic inflammation type, 3M / 3F), follicular edema group (5 cases of follicular edema type, 3M / 2F), papilloma group (5 cases of papilloma type, 2M / 3F), intestinal adenomatous group (7 cases of intestinal adenomatous type, 4M / 3F). All cases were newly diagnosed and had no history of drug treatment. Another 5 cases with normal bladder served as the control group. There was no significant difference in the age of the subjects in each group. All patients and those with normal bladder had normal heart, lung, liver, kidney and hematopoietic functions. Normal bladder refers to healthy volunteers with no abnormal prolifer...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

A use of biomarkers in preparation of a cystitis glandularis diagnostic reagent is disclosed. The cystitis glandularis includes a chronic inflammation type, a follicle edema type, a papilloma type and an intestine adenoma type. The biomarkers include methylcrotonyl carnitine, lysophosphatidyl ethanolamine and arachidonic acid. When the methylcrotonyl carnitine, the lysophosphatidyl ethanolamine and the arachidonic acid are combined for diagnosis and distinguishing of patients with cystitis glandularis from persons with normal bladders, the area under the ROC curve is 0.958, sensitivity and specificity are 96.6% and 96.1% respectively, and the area under the ROC curve when each biomarker is used separately is less than 0.7. By adoption of the diagnostic reagent, cystitis glandularis can be diagnosed and classified without the need of an intervention means, only a small amount of blood of a patient is needed, detection is free of taboos, and disadvantages of cystoscopy are overcome.

Description

technical field [0001] The invention belongs to the field of diagnostic reagents, and in particular relates to the use of biomarkers for preparing diagnostic typing reagents for cystitis glandularis. Background technique [0002] Cystitis glandularis (CG) is a relatively rare non-neoplastic inflammatory lesion. It is a lesion in which epithelial hyperplasia and metaplasia coexist. Cracks form branched and annular lumens, and glandular metaplasia appears in the center to form glandular structures. At the same time, lymphocytes and plasma cells infiltrate, so it is called glandular cystitis. To put it simply, cystitis glandularis is a kind of abnormal proliferation and metaplasia of mucous glands in bladder mucosa and submucosa, its incidence rate is increasing day by day, and it is closely related to bladder cancer (Yang Anqing et al. Expression in cystitis and its clinical significance, 2016). Whether cystitis glandularis is a precancerous lesion is currently controversial...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
IPC IPC(8): G01N33/48G01N30/02C12Q1/6883C12Q1/6886
CPCC12Q1/6883C12Q2600/158C12Q2600/178G01N30/02G01N33/48G01N2800/34
Inventor 不公告发明人
Owner 北京华瑞康源生物科技发展有限公司